Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.

Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordmüller B, Lell B; VEBCON Consortium, Krishna S, Kremsner PG.

PLoS Med. 2017 Oct 6;14(10):e1002402. doi: 10.1371/journal.pmed.1002402. eCollection 2017 Oct.

2.

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV.

Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, Lohse A, Krähling V, Eickmann M, Becker S; VEBCON Consortium, Thiébaut R, Altfeld M, Addo MM.

Cell Rep. 2017 Aug 29;20(9):2251-2261. doi: 10.1016/j.celrep.2017.08.023.

3.

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.

Dahlke C, Kasonta R, Lunemann S, Krähling V, Zinser ME, Biedenkopf N, Fehling SK, Ly ML, Rechtien A, Stubbe HC, Olearo F, Borregaard S, Jambrecina A, Stahl F, Strecker T, Eickmann M, Lütgehetmann M, Spohn M, Schmiedel S, Lohse AW, Becker S, Addo MM; VEBCON Consortium.

EBioMedicine. 2017 May;19:107-118. doi: 10.1016/j.ebiom.2017.03.045. Epub 2017 Apr 5.

4.

Corrigendum: Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells.

Hölzer M, Krähling V, Amman F, Barth E, Bernhart SH, Carmelo VA, Collatz M, Doose G, Eggenhofer F, Ewald J, Fallmann J, Feldhahn LM, Fricke M, Gebauer J, Gruber AJ, Hufsky F, Indrischek H, Kanton S, Linde J, Mostajo N, Ochsenreiter R, Riege K, Rivarola-Duarte L, Sahyoun AH, Saunders SJ, Seemann SE, Tanzer A, Vogel B, Wehner S, Wolfinger MT, Backofen R, Gorodkin J, Grosse I, Hofacker I, Hoffmann S, Kaleta C, Stadler PF, Becker S, Marz M.

Sci Rep. 2017 Jan 11;7:39421. doi: 10.1038/srep39421. No abstract available.

5.

Functional Characterization of Adaptive Mutations during the West African Ebola Virus Outbreak.

Dietzel E, Schudt G, Krähling V, Matrosovich M, Becker S.

J Virol. 2017 Jan 3;91(2). pii: e01913-16. doi: 10.1128/JVI.01913-16. Print 2017 Jan 15.

6.

Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells.

Hölzer M, Krähling V, Amman F, Barth E, Bernhart SH, Carmelo VA, Collatz M, Doose G, Eggenhofer F, Ewald J, Fallmann J, Feldhahn LM, Fricke M, Gebauer J, Gruber AJ, Hufsky F, Indrischek H, Kanton S, Linde J, Mostajo N, Ochsenreiter R, Riege K, Rivarola-Duarte L, Sahyoun AH, Saunders SJ, Seemann SE, Tanzer A, Vogel B, Wehner S, Wolfinger MT, Backofen R, Gorodkin J, Grosse I, Hofacker I, Hoffmann S, Kaleta C, Stadler PF, Becker S, Marz M.

Sci Rep. 2016 Oct 7;6:34589. doi: 10.1038/srep34589. Erratum in: Sci Rep. 2017 Jan 11;7:39421.

7.

Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.

Geisen C, Kann G, Strecker T, Wolf T, Schüttfort G, van Kraaij M, MacLennan S, Rummler S, Weinigel C, Eickmann M, Fehling SK, Krähling V, Seidl C, Seifried E, Schmidt M, Schäfer R.

Vox Sang. 2016 May;110(4):329-35. doi: 10.1111/vox.12376. Epub 2016 Jan 14.

PMID:
26766162
8.

Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection.

Dowall SD, Callan J, Zeltina A, Al-Abdulla I, Strecker T, Fehling SK, Krähling V, Bosworth A, Rayner E, Taylor I, Charlton S, Landon J, Cameron I, Hewson R, Nasidi A, Bowden TA, Carroll MW.

J Infect Dis. 2016 Apr 1;213(7):1124-33. doi: 10.1093/infdis/jiv565. Epub 2015 Dec 28.

9.

Transcriptional Regulation in Ebola Virus: Effects of Gene Border Structure and Regulatory Elements on Gene Expression and Polymerase Scanning Behavior.

Brauburger K, Boehmann Y, Krähling V, Mühlberger E.

J Virol. 2015 Dec 9;90(4):1898-909. doi: 10.1128/JVI.02341-15. Print 2016 Feb 15.

10.

Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus.

Krähling V, Becker D, Rohde C, Eickmann M, Eroğlu Y, Herwig A, Kerber R, Kowalski K, Vergara-Alert J, Becker S; European Mobile Laboratory consortium.

Med Microbiol Immunol. 2016 Apr;205(2):173-83. doi: 10.1007/s00430-015-0438-6. Epub 2015 Oct 16.

PMID:
26475282
11.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

PMID:
26248510
12.

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.

Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, Biedenkopf N, Krähling V, Tully CM, Edwards NJ, Bentley EM, Samuel D, Labbé G, Jin J, Gibani M, Minhinnick A, Wilkie M, Poulton I, Lella N, Roberts R, Hartnell F, Bliss C, Sierra-Davidson K, Powlson J, Berrie E, Tedder R, Roman F, De Ryck I, Nicosia A, Sullivan NJ, Stanley DA, Mbaya OT, Ledgerwood JE, Schwartz RM, Siani L, Colloca S, Folgori A, Di Marco S, Cortese R, Wright E, Becker S, Graham BS, Koup RA, Levine MM, Volkmann A, Chaplin P, Pollard AJ, Draper SJ, Ballou WR, Lawrie A, Gilbert SC, Hill AV.

N Engl J Med. 2016 Apr 28;374(17):1635-46. doi: 10.1056/NEJMoa1411627. Epub 2015 Jan 28.

13.

Investigating the zoonotic origin of the West African Ebola epidemic.

Marí Saéz A, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Düx A, Kühl HS, Kaba M, Regnaut S, Merkel K, Sachse A, Thiesen U, Villányi L, Boesch C, Dabrowski PW, Radonić A, Nitsche A, Leendertz SA, Petterson S, Becker S, Krähling V, Couacy-Hymann E, Akoua-Koffi C, Weber N, Schaade L, Fahr J, Borchert M, Gogarten JF, Calvignac-Spencer S, Leendertz FH.

EMBO Mol Med. 2015 Jan;7(1):17-23. doi: 10.15252/emmm.201404792.

14.

Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells.

Bharat TA, Riches JD, Kolesnikova L, Welsch S, Krähling V, Davey N, Parsy ML, Becker S, Briggs JA.

PLoS Biol. 2011 Nov;9(11):e1001196. doi: 10.1371/journal.pbio.1001196. Epub 2011 Nov 15.

15.

Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Schmidt KM, Schümann M, Olejnik J, Krähling V, Mühlberger E.

J Infect Dis. 2011 Nov;204 Suppl 3:S861-70. doi: 10.1093/infdis/jir308.

16.

Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection.

Krähling V, Dolnik O, Kolesnikova L, Schmidt-Chanasit J, Jordan I, Sandig V, Günther S, Becker S.

PLoS Negl Trop Dis. 2010 Aug 24;4(8):e802. doi: 10.1371/journal.pntd.0000802.

17.

Electron tomography reveals the steps in filovirus budding.

Welsch S, Kolesnikova L, Krähling V, Riches JD, Becker S, Briggs JA.

PLoS Pathog. 2010 Apr 29;6(4):e1000875. doi: 10.1371/journal.ppat.1000875.

18.

Marburg virus evades interferon responses by a mechanism distinct from ebola virus.

Valmas C, Grosch MN, Schümann M, Olejnik J, Martinez O, Best SM, Krähling V, Basler CF, Mühlberger E.

PLoS Pathog. 2010 Jan 15;6(1):e1000721. doi: 10.1371/journal.ppat.1000721.

19.
20.

The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus.

Enterlein S, Schmidt KM, Schümann M, Conrad D, Krähling V, Olejnik J, Mühlberger E.

J Virol. 2009 May;83(9):4508-19. doi: 10.1128/JVI.02429-08. Epub 2009 Feb 18.

21.

Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity.

Krähling V, Stein DA, Spiegel M, Weber F, Mühlberger E.

J Virol. 2009 Mar;83(5):2298-309. doi: 10.1128/JVI.01245-08. Epub 2008 Dec 24.

Supplemental Content

Loading ...
Support Center